| Patient | Alan Turing |
|---|---|
| Date of birth | 1985-06-23 |
| Identifiers | MRN HR-ML007-SYN; SSN (made up) 000-07-6290 |
| Document date | 2026-06-09 |
| Author | Rupert Hallam, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Eight-week review of hormone recovery and depression treatment. [S]
Mr. Turing returns eight weeks after his first visit, about eleven weeks after the last estrogen injection. The breast tenderness is less and he no longer notices it when running. Morning erections returned three weeks ago and his libido is coming back. He has had seven psychotherapy sessions and runs about 25 km a week. His mood is somewhat better, but he still feels flat most days, has little pleasure outside work, and wakes early. He has had no suicidal thoughts. After the last visit he asked to think about medicine; today, after a discussion of sertraline, mirtazapine, and bupropion and their effects on sexual function, weight, sleep, and blood pressure, he chose bupropion. He has no history of seizures, head injury, or an eating disorder and drinks little alcohol. [S]
| Element | Detail |
|---|---|
| Breasts | Less tender; no discharge |
| Sexual function | Morning erections back for three weeks; libido returning |
| Psychotherapy | Seven sessions |
| Running | About 25 km a week |
| Safety | No suicidal thoughts |
| PHQ-9 | 12, down from 15 |
| System | Result | Finding |
|---|---|---|
| Breast | Positive | Mild tenderness on pressure only; no discharge |
| Genitourinary | Negative | Erections returning; no testicular symptoms |
| Neurological | Negative | No seizures, fainting, or head injury ever |
| Psychiatric | Positive | Flat mood and early waking; no suicidal thoughts, elevated mood, or racing thoughts |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Cholecalciferol 1,000 units (25 mcg) oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-04-14 | active | S |
| Bupropion extended-release 150 mg oral tablet, one tablet by mouth each morning | One tablet by mouth each morning | Oral route | 2026-06-09 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-06-09 | Body height | 178 | cm | S |
| 2026-06-09 | Body weight | 70.1 | kg | S |
| 2026-06-09 | Body mass index (BMI) [Ratio] | 22.1 | kg/m2 | S |
| 2026-06-09 | Systolic blood pressure | 118 | mm[Hg] | S |
| 2026-06-09 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-06-09 | Heart rate | 58 | /min | S |
| 2026-06-09 | Respiratory rate | 14 | /min | S |
| 2026-06-09 | Body temperature | 36.6 | Cel | S |
| 2026-06-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-06-09 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 12 | {score} | S | ||
| 2026-06-09 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 6 | {score} | S | ||
| 2026-06-09 | Testosterone [Mass/volume] in Serum or Plasma | 238 | ng/dL | 264-916 ng/dL | Low | S |
| 2026-06-09 | Estradiol (E2) [Mass/volume] in Serum or Plasma | 26 | pg/mL | 7.6-42.6 pg/mL | Normal | S |
| 2026-06-09 | Lutropin [Units/volume] in Serum or Plasma | 2.4 | m[IU]/mL | 1.7-8.6 m[IU]/mL | Normal | S |
| 2026-06-09 | Follitropin [Units/volume] in Serum or Plasma | 3.1 | m[IU]/mL | 1.5-12.4 m[IU]/mL | Normal | S |
| 2026-06-09 | Prolactin [Mass/volume] in Serum or Plasma | 12.4 | ng/mL | 4-15.2 ng/mL | Normal | S |
| 2026-06-09 | Hemoglobin [Mass/volume] in Blood | 13.6 | g/dL | 13.2-16.6 g/dL | Normal | S |
Vital signs recorded on 2026-06-09; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Lean; more animated than at intake |
| Breast | Examined with his agreement: glandular tissue about 3 cm behind each nipple, softer and only mildly tender; no discrete mass, skin change, discharge, or nodes |
| Mental status | Alert; mood "better, but grey"; affect mildly constricted and reactive; thought process linear; no suicidal ideation; insight and judgment good |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Bilateral gynecomastia, tender, about 4 cm of firm glandular tissue behind each nipple, after a year of high-dose estrogen; synthetic modern diagnosis linked to the documented breast growth from his hormone treatment | active | confirmed | N62 | S — Synthetic modern diagnosis. That the hormone treatment caused breast growth is reported in the sources (D, mentioned once in his own words); the examination findings are synthetic. |
| Suppressed testosterone and gonadotropins from exogenous estrogen (drug-induced hypogonadotropic hypogonadism), with low libido, erectile difficulty, and fatigue | active | confirmed | E23.1 | S — Synthetic consequence of high-dose estrogen, which suppresses LH and FSH; recovery is expected once it stops. |
| Adverse effects of high-dose estrogen given for a year without free and informed consent, as the alternative to imprisonment | active | confirmed | T38.5X5A | S — Synthetic modern framing of the documented hormone treatment imposed after his conviction (D); in the modern episode it is recorded as iatrogenic harm. |
| Major depressive disorder, single episode, moderate, after prosecution and coerced hormone treatment; synthetic modern diagnosis (no depression diagnosis is documented in his lifetime) | active | confirmed | F32.1 | S — Synthetic modern diagnosis. That he sought Jungian analysis after the trial is documented (D); calling his state then a depressive illness is a retrospective interpretation (R). |
| Vitamin D insufficiency (25-hydroxyvitamin D 22 ng/mL) | active | confirmed | E55.9 | S — Synthetic finding of the bone-health workup. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Breast examination for size, tenderness, and any discrete mass | Every visit until the gynecomastia settles | Completed today | Glandular tissue about 3 cm behind each nipple, softer, mildly tender; no discrete mass |
| Laboratory | Testosterone, estradiol, LH, and FSH | Every 6 to 8 weeks after the exposure stops, until normal | Completed today | Testosterone 238 ng/dL (low, rising); estradiol 26 pg/mL; LH 2.4 and FSH 3.1 mIU/mL, now in range |
| Laboratory | Prolactin after the estrogen clears | Repeat once after a raised value | Completed today | 12.4 ng/mL, normal, down from 21.6; the rise was estrogen-related |
| Laboratory | Hemoglobin while testosterone is low | With each hormone check until normal | Completed today | 13.6 g/dL, back in range |
| Medication safety | Testosterone therapy | Only for persistent, symptomatic, confirmed testosterone deficiency | Not indicated | Not given while the axis recovers: it would suppress LH and FSH again and is not indicated for a transient, drug-induced low testosterone |
| Survey | PHQ-9 | Baseline, then at least monthly during acute treatment; every 2 to 4 weeks in continuation | Completed today | 12, down 20 percent from 15: partial response; bupropion added. Six weeks since the last score, two weeks beyond the monthly interval, because this review was timed to the hormone tests; no harm, as he had weekly therapy sessions and no suicidal thoughts |
| Survey | GAD-7 | With the PHQ-9 when anxiety symptoms were present at baseline | Completed today | 6, down from 8 |
| Survey | Suicide risk reassessment (C-SSRS Since Last Visit and PHQ-9 item 9) | Every visit during active treatment | Completed today | No suicidal thoughts, intent, plan, or behavior since the last visit; PHQ-9 item 9 scored 0. Protective factors unchanged; safety plan reviewed |
| Survey | Bipolar screen before starting an antidepressant | At the initial workup; repeat if hypomanic features emerge | Completed today | Still no history of elevated mood, reduced need for sleep, or racing thoughts |
| Medication safety | Antidepressant tolerability check two weeks after starting | 2 weeks after starting and after each dose change | Due | Nurse telephone check booked for two weeks from today |
| Self-management | Psychotherapy, sleep, running, and social contact | Every visit during active treatment | Completed today | Seven sessions; running about 25 km a week; early waking |
| Laboratory | Lithium, anticonvulsant, or antipsychotic monitoring (levels, metabolic tests, AIMS) | Only on those drugs | Not indicated | Not on any of these drugs |
Goal progress:
Guideline basis: EAA clinical practice guidelines: gynecomastia evaluation and management (2019); Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline (2018); VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)
Follow-up: Nurse telephone check in two weeks; review in eight weeks with hormone tests and PHQ-9. Next scheduled visit 2026-08-04: sixteen-week review of hormone recovery and depression treatment. [S]